肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化

doi:10.3969/j.issn.1672-5069.2021.02.024

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)患者血清常见的癌基因和抑癌基因水平变化。方法 2017年7月～2020年7月我院收治的慢性乙型肝炎患者40例,代偿期乙型肝炎肝硬化患者25例,失代偿期乙型肝炎肝硬化患者31例,HCC 患者50例和同期体检的健康人40例,采用ELISA法检测血清癌基因转化基因(N-ras)、增殖相关基因(C-myc)、成纤维细胞生长因子(FGF)2、丝/苏氨酸激酶(PLK)1和抑癌基因铁调素(hepcidin)、清道夫受体(SCAR)A5、细胞周期依赖性蛋白激酶抑制剂(P16)蛋白水平。结果 HCC组血清癌基因N-ras、C-myc、FGF2和PLK1蛋白水平分别为(17.9±2.4)pg/mL、(16.2±2.0)pg/mL、(19.0±3.2)pg/mL和(15.4±1.9)pg/mL,显著高于失代偿期肝硬化患者【分别为(10.3±1.4)pg/mL、(10.0±1.2)pg/mL、(10.2±1.4)pg/mL和(9.0±1.1)pg/mL,P＜0.05】或代偿期肝硬化患者【分别为(9.9±1.2)pg/mL、(9.9±1.1)pg/mL、(10.0±1.3)pg/mL和(9.1±1.0)pg/mL,P＜0.05】或慢性乙型肝炎患者【分别为(9.8±1.1)pg/mL、(9.7±1.1)pg/mL、(9.9±1.2)pg/mL和(9.0±1.0)pg/mL,P＜0.05】或健康人【分别为(1.2±0.2)pg/mL、(1.1±0.1)pg/mL、(1.1±0.2)pg/mL和(0.9±0.1)pg/mL,P＜0.05】;HCC患者血清hepcidin、SCARA5和P16蛋白水平分别为(1.1±0.3)pg/mL、(1.3±0.3)pg/mL和(1.7±0.4)pg/mL,显著低于失代偿期肝硬化患者【分别为(5.3±0.7)pg/mL、(7.2±1.1)pg/mL和(6.4±0.8)pg/mL,P＜0.05】或代偿期肝硬化患者【分别为(5.6±0.8)pg/mL、(7.3±1.1)pg/mL和(6.3±0.8)pg/mL,P＜0.05】或慢性乙型肝炎患者【分别为(5.4±0.7)pg/mL、(7.9±1.1)pg/mL和(6.5±1.0)pg/mL,P＜0.05】或健康人【分别为(12.9±1.2)pg/mL、(14.4±1.3)pg/mL和(11.6±0.9)pg/mL,P＜0.05】。结论肝细胞癌患者血清癌基因水平升高,而抑癌基因水平降低,可能参与了HCC的发病过程,其临床意义仍有待探讨。

关键词: 肝细胞癌, 癌基因, 抑癌基因

Abstract: Objective The aim of this study was to investigate serum oncogene and tumor suppressor gene level changes in patients with hepatocellular carcinoma (HCC).Methods 40 patients with chronic hepatitis B (CHB), 25 patients with compensated hepatitis B liver cirrhosis (LC), 31 patients with decompensated hepatitis B LC, 50 patients with HCC and 40 healthy persons were enrolled in our hospital between July 2017 and July 2020, and serum oncogene transformation of participants (N-ras), proliferation related genes (C-myc), fibroblast growth factor (FGF) 2, silk/threonine kinase (PLK) 1 as well as tumor-suppressor genes iron element (hepcidin), scavenger receptors (SCAR) A5, and cell cycle dependent protein kinase inhibitor (P16) protein were detected by ELISA.Results Serum N-ras, C-myc, FGF2 and PLK1 levels in patients with HCC were (17.9±2.4)pg/mL, (16.2±2.0)pg/mL,(19.0±3.2)pg/mL and (15.4±1.9)pg/mL, all significantly higher than 【(10.3±1.4)pg/mL,(10.0±1.2)pg/mL,(10.2±1.4)pg/mL and (9.0±1.1)pg/mL, respectively, P＜0.05】 in patients with decompensated LC or 【(9.9±1.2)pg/mL,(9.9±1.1)pg/mL,(10.0±1.3)pg/mL and (9.1±1.0)pg/mL, respectively,P＜0.05】 in patients with compensated LC or 【(9.8±1.1)pg/mL,(9.7±1.1)pg/mL,(9.9±1.2)pg/mL and (9.0±1.0)pg/mL, respectively, P＜0.05】 in patients with CHB or 【(1.2±0.2)pg/mL, (1.1±0.1)pg/mL, (1.1±0.2)pg/mL and (0.9±0.1)pg/mL, respectively, P＜0.05】 in healthy persons; serum hepcidin, SCARA5 and P16 levels in patients with HCC were (1.1±0.3)pg/mL,(1.3±0.3)pg/mL and (1.7±0.4)pg/mL, all significantly lower than 【(5.3±0.7)pg/mL,(7.2±1.1)pg/mL and (6.4±0.8)pg/mL, respectively, P＜0.05】 in patients with decompensated LC or 【(5.6±0.8)pg/mL,(7.3±1.1)pg/mL and (6.3±0.8)pg/mL, respectively, P＜0.05】 in patients with compensated LC or 【(5.4±0.7)pg/mL,(7.9±1.1)pg/mL and (6.5±1.0)pg/mL, respectively, P＜0.05】 in patients with CHB or 【(12.9±1.2)pg/mL, (14.4±1.3)pg/mL and (11.6±0.9)pg/mL, respectively, P＜0.05】 in healthy individuals.Conclusion The up-regulation of N-ras, c-myc, FGF2 and PLK1 and down-regulation of hepcidin, scara5 and p16 occur in patients with HCC, which might be involved in the hepatocarcinogenesis.

Key words: Hepatoma, Oncogene, Tumor suppressor gene

陈少华, 吴哲, 魏志鸿, 陈鹏. 肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 244-247.

Chen Shaohua, Wu Zhe, Wei Zhihong, et al. Serum oncogene and tumor suppressor gene levels in patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2021, 24(2): 244-247.

参考文献

[1] Jabbour TE, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists' review. World J Gastroenterol, 2019, 25(14):1653-1665.
[2] Golabi P, Rhea L, Henry L, et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int, 2019, 13(6):688-694.
[3] Budny A ,Kozłowski P , Kamińska M, et al. Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski, 2017, 43(255):133-139.
[4] Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev, 2018, 38(2):741-767.
[5] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[6] Cartier F , Indersie E , Lesjean S, et al. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget, 2017, 8(25):41211-41226.
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32.
[8] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[9] 曹艳, 王艳. 基于死因监测青岛市居民2008-2012年原发性肝癌死亡分析. 中华肿瘤防治杂志, 2017, 24(9):579-583.
[10] 管晨滔, 赵宏, 李新庆, 等. 肝细胞癌患者的基本特征及其生存分析. 中华肿瘤杂志, 2017, 39(3):231-235.
[11] 罗准, 崔巍. 肝癌分子发病机制中非编码RNA的研究进展. 中华肝脏病杂志, 2018, 26(10):797-800.
[12] Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat RevGastroenterol Hepatol, 2018, 15(3):137-151.
[13] Delogu S, Wang C, Cigliano A, et al. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6(4):2222-2234.
[14] Kress TR, Pellanda P, Pellegrinet L, et al. Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors. Cancer Res, 2016, 76(12):3463-3472.
[15] Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell, 2017, 32(1):57-70.
[16] Yim SY, Shim JJ, Shin JH, et al. Integrated genomic comparison of mouse models reveals their clinical resemblance to human liver cancer. Mol Cancer Res, 2018, 16(11):1713-1723.
[17] Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med, 2016, 38(1):3-15.
[18] Ruf S, Heberle AM, Langelaar-Makkinje M, et al. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy, 2017, 13(3):486-505.
[19] Zhao N, Maxson JE, Zhang RH, et al. Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver. J Biol Chem, 2016, 291(23):12322-12335.
[20] Liu H, Hu J, Pan H, et al. CSN5 Promotes hepatocellular carcinoma progression by SCARA5 inhibition through suppressing β-catenin ubiquitination. Dig Dis Sci, 2018, 63(1):155-165.